After Sanofi leadership telegraphed an upsized appetite for business development last month, signals have emerged that the ...
Biogen is visualizing life amid disease progression in its newest Friedreich ataxia (FA)-focused campaign, reminding ...
The FDA has slammed Johnson & Johnson over misleading claims about its bladder cancer drug Inlexzo, accusing the pharma ...
Lotte Biologics, a South Korea-headquartered CDMO established in 2022, has inked a large manufacturing deal with an unnamed ...
Novartis is gearing up to defend its growth trajectory against a steep wave of patent expirations in the early 2030s, as the ...
Underscoring how crowded the U.S. market for generalized myasthenia gravis (gMG) has become, the FDA on Wednesday approved ...
Salerno Pharmaceuticals of Tulsa, Oklahoma, is facing pressure from the FDA to yank its lone commercial product. | In a ...
After delaying the phase 3 readout of its Alzheimer’s psychosis program for Cobenfy earlier this year, Bristol Myers Squibb ...
AI has moved from experimentation to expectation. As tools become widely available, competitive intelligence clients are no ...
Beren Therapeutics has officially seen a cyclodextrin therapy across the finish line, scoring an FDA approval in Niemann-Pick disease type C (NPC) that’s over a decade in the making.
AriBio’s erectile dysfunction med-turned Alzheimer’s disease candidate mirodenafil has delivered some mixed results from a ...
The White House is reportedly pulling the nomination for Heidi Overton, M.D., Ph.D., to lead the FDA just hours before the ...